|
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM accounts for 1% to 2% of all forms of AML and has been associated with a younger age at diagnosis, a poor response to standard induction chemotherapy, and very poor long-term prognosis.
|
31711889 |
2020 |
|
Acute monocytic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Suppression of GPR56 expression by pyrrole-imidazole polyamide represents a novel therapeutic drug for AML with high EVI1 expression.
|
30214063 |
2018 |
|
Acute monocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML.
|
28538183 |
2017 |
|
Acute monocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
EVI1(-) t(9;11) AMLs had lower WBC counts, more commonly FAB M5 morphology, and frequently had additional trisomy 8 (39.6%; P < .001).
|
23008312 |
2013 |
|
Acute monocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
|
22553314 |
2012 |
|
Acute monocytic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A high MEBE expression score is an unfavorable prognostic marker in MDS and is associated with an increased risk for progression to AML.
|
22488406 |
2012 |
|
Acute monocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, the expression of these markers and of EVI1 and CDKN1B was determined using oligonucleotide microarrays in 286 AML comprising all cytogenetic groups.
|
22072540 |
2012 |
|
Acute monocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
EVI1+ was found in 20/213 (9%) of children with de novo AML, and in 4/8 with secondary AML.
|
20357826 |
2010 |
|
Acute monocytic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We argue that EVI1/ME quantitative expression analysis should be implemented in the molecular diagnostic procedures of AML.
|
18272813 |
2008 |
|
Acute monocytic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
|
18181178 |
2008 |
|
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A novel EVI1 gene family, MEL1, lacking a PR domain (MEL1S) is expressed mainly in t(1;3)(p36;q21)-positive AML and blocks G-CSF-induced myeloid differentiation.
|
12816872 |
2003 |
|
Acute monocytic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
|
12393383 |
2003 |
|
Acute monocytic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Establishment of a novel human myeloid leukaemia cell line (HNT-34) with t(3;3)(q21;q26), t(9;22)(q34;q11) and the expression of EVI1 gene, P210 and P190 BCR/ABL chimaeric transcripts from a patient with AML after MDS with 3q21q26 syndrome.
|
9266939 |
1997 |
|
Acute monocytic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
EVI1 is also expressed by cells from AML patients with chromosome rearrangements involving band 3q26, the putative location of the EVI1 gene, but expression of this gene is not detected in normal bone marrow.
|
8412328 |
1993 |